Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad and AstraZeneca Expand Research Collaboration on Lynparza

SALT LAKE CITY, April 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the...
March 20, 2015 02:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients...
March 17, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for Talazoparib

SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded...
March 05, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform

SALT LAKE CITY, March 5, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc., (Nasdaq:MYGN) today announced the launch of immunoassay services based on the...
March 04, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that...
March 02, 2015 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the Barclays Global Healthcare Conference

SALT LAKE CITY, March 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetic Laboratories, is scheduled to present at the...
February 24, 2015 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Board Approves $200 Million Increase in Share Repurchase Program

SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share...
February 06, 2015 13:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink...
February 03, 2015 16:10 ET | Source: Myriad Genetics, Inc.

Myriad Announces Retirement of Peter D. Meldrum, President and CEO

SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his...
February 03, 2015 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results

Revenues of $184.4 Million Adjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk™ Hereditary Cancer Revenues of $85.1 Million BRACAnalysis CDx™ Approved by the...